Drug Name: Krazati

Active Ingredient: adagrasib

Indications: To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy

Approval Date: 12/12/2022

Company: Mirati Therapeutics, Inc.

Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *